Global Hospital Acquired Pneumonia Market

Hospital Acquired Pneumonia Comprehensive Study by Type (Oral Care Kit, Toothbrush, Swab, Moisturizer, Mouth Wash, Suction Tools), End-user (Hospitals, Rehabilitation Centers, Home Care Settings), Drug Class (Antibacterial drug, Antiviral drugs, Others) Players and Region - Global Market Outlook to 2030

Hospital Acquired Pneumonia Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 3.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Hospital Acquired Pneumonia
Hospital-acquired pneumonia is defined as pneumonia which occurs 48 hours or more after admission. It is a lower respiratory infection that mainly does not incubate at the time of hospital admission but also presents clinically more than 2 or 3 days after hospitalization. A most common cause of hospital-acquired pneumonia is hospitalization in an acute-care hospital within the preceding 90 days, intravenous therapy for wound care within the preceding 30 days, residence in a long-term care facility, among others. The common bacteria involved in hospital-acquired pneumonia are P aeruginosa, Staphylococcus aureus, S aureus, methicillin-resistant S aureus, among others. According to the Centers for Disease Control and Prevention, 1 in 25 patients affected infection and more than 75,000 deaths each year. Hence, this data shows that the rising number of patients will affect the growth of the market in the future.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR3.2%


The hospital-acquired pneumonia market is highly fragmented in nature with a large number of international as well as regional players operating in the market. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Hospital Acquired Pneumonia market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline plc (United Kingdom), Achaogen, Inc. (United States), Cubist Pharmaceutical (United States), Aridis Pharmaceutical (United States), Bayer Healthcare (Germany), AstraZeneca PLC (United Kingdom), Basilea Pharmaceutica Ltd. (Switzerland), Merck & Co., Inc., (United States), Meiji Seika Pharma Co., Ltd. (Japan) and Valneva SE. (France) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Hospital Acquired Pneumonia market by Type (Oral Care Kit, Toothbrush, Swab, Moisturizer, Mouth Wash and Suction Tools) and Region.



On the basis of geography, the market of Hospital Acquired Pneumonia has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-user, the sub-segment i.e. Hospitals will boost the Hospital Acquired Pneumonia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Antibacterial drug will boost the Hospital Acquired Pneumonia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising Demand in Combination Therapy for the Treatment of HAP

Market Growth Drivers:
Unmet Demand Owing to Lack of Available Treatment for MDR Microorganisms and Incidence of HAP is more prevalent in the medical as well as surgical Intensive Care Units

Challenges:
Lack of awareness of Hospital-acquired Pneumonia Drugs and Growing cases of MDR microorganisms

Restraints:
Issue related to high Prices of Hospital-acquired pneumonia Products

Opportunities:
Rising Demand from Emerging Economics such as China and India and Government Initiatives to expand the hospital Acquired Pneumonia Market

Market Leaders and their expansionary development strategies
In December 2023, AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. The proposed acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca’s Vaccines & Immune Therapies
In June 2019, Merck received FDA approval for the Zerbaxa drug used to treat ventilator-associated pneumonia and hospital-acquired bacterial pneumonia. This strategy expanded the firm’s pneumonia therapeutics portfolio.


Key Target Audience
Manufactures Hospital-acquired pneumonia Drugs, Research and Development (R&D) Companies, Research Organization, Federal Agencies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Oral Care Kit
  • Toothbrush
  • Swab
  • Moisturizer
  • Mouth Wash
  • Suction Tools
By End-user
  • Hospitals
  • Rehabilitation Centers
  • Home Care Settings

By Drug Class
  • Antibacterial drug
  • Antiviral drugs
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Unmet Demand Owing to Lack of Available Treatment for MDR Microorganisms
      • 3.2.2. Incidence of HAP is more prevalent in the medical as well as surgical Intensive Care Units
    • 3.3. Market Challenges
      • 3.3.1. Lack of awareness of Hospital-acquired Pneumonia Drugs
      • 3.3.2. Growing cases of MDR microorganisms
    • 3.4. Market Trends
      • 3.4.1. Rising Demand in Combination Therapy for the Treatment of HAP
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hospital Acquired Pneumonia, by Type, End-user, Drug Class and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hospital Acquired Pneumonia (Value)
      • 5.2.1. Global Hospital Acquired Pneumonia by: Type (Value)
        • 5.2.1.1. Oral Care Kit
        • 5.2.1.2. Toothbrush
        • 5.2.1.3. Swab
        • 5.2.1.4. Moisturizer
        • 5.2.1.5. Mouth Wash
        • 5.2.1.6. Suction Tools
      • 5.2.2. Global Hospital Acquired Pneumonia by: End-user (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Rehabilitation Centers
        • 5.2.2.3. Home Care Settings
      • 5.2.3. Global Hospital Acquired Pneumonia by: Drug Class (Value)
        • 5.2.3.1. Antibacterial drug
        • 5.2.3.2. Antiviral drugs
        • 5.2.3.3. Others
      • 5.2.4. Global Hospital Acquired Pneumonia Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Hospital Acquired Pneumonia (Volume)
      • 5.3.1. Global Hospital Acquired Pneumonia by: Type (Volume)
        • 5.3.1.1. Oral Care Kit
        • 5.3.1.2. Toothbrush
        • 5.3.1.3. Swab
        • 5.3.1.4. Moisturizer
        • 5.3.1.5. Mouth Wash
        • 5.3.1.6. Suction Tools
      • 5.3.2. Global Hospital Acquired Pneumonia by: End-user (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Rehabilitation Centers
        • 5.3.2.3. Home Care Settings
      • 5.3.3. Global Hospital Acquired Pneumonia by: Drug Class (Volume)
        • 5.3.3.1. Antibacterial drug
        • 5.3.3.2. Antiviral drugs
        • 5.3.3.3. Others
      • 5.3.4. Global Hospital Acquired Pneumonia Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Hospital Acquired Pneumonia (Price)
      • 5.4.1. Global Hospital Acquired Pneumonia by: Type (Price)
  • 6. Hospital Acquired Pneumonia: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Achaogen, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cubist Pharmaceutical (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Aridis Pharmaceutical (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer Healthcare (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AstraZeneca PLC (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Basilea Pharmaceutica Ltd. (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co., Inc., (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Meiji Seika Pharma Co., Ltd. (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Valneva SE. (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hospital Acquired Pneumonia Sale, by Type, End-user, Drug Class and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hospital Acquired Pneumonia (Value)
      • 7.2.1. Global Hospital Acquired Pneumonia by: Type (Value)
        • 7.2.1.1. Oral Care Kit
        • 7.2.1.2. Toothbrush
        • 7.2.1.3. Swab
        • 7.2.1.4. Moisturizer
        • 7.2.1.5. Mouth Wash
        • 7.2.1.6. Suction Tools
      • 7.2.2. Global Hospital Acquired Pneumonia by: End-user (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Rehabilitation Centers
        • 7.2.2.3. Home Care Settings
      • 7.2.3. Global Hospital Acquired Pneumonia by: Drug Class (Value)
        • 7.2.3.1. Antibacterial drug
        • 7.2.3.2. Antiviral drugs
        • 7.2.3.3. Others
      • 7.2.4. Global Hospital Acquired Pneumonia Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Hospital Acquired Pneumonia (Volume)
      • 7.3.1. Global Hospital Acquired Pneumonia by: Type (Volume)
        • 7.3.1.1. Oral Care Kit
        • 7.3.1.2. Toothbrush
        • 7.3.1.3. Swab
        • 7.3.1.4. Moisturizer
        • 7.3.1.5. Mouth Wash
        • 7.3.1.6. Suction Tools
      • 7.3.2. Global Hospital Acquired Pneumonia by: End-user (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Rehabilitation Centers
        • 7.3.2.3. Home Care Settings
      • 7.3.3. Global Hospital Acquired Pneumonia by: Drug Class (Volume)
        • 7.3.3.1. Antibacterial drug
        • 7.3.3.2. Antiviral drugs
        • 7.3.3.3. Others
      • 7.3.4. Global Hospital Acquired Pneumonia Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Hospital Acquired Pneumonia (Price)
      • 7.4.1. Global Hospital Acquired Pneumonia by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hospital Acquired Pneumonia: by Type(USD Million)
  • Table 2. Hospital Acquired Pneumonia Oral Care Kit , by Region USD Million (2018-2023)
  • Table 3. Hospital Acquired Pneumonia Toothbrush , by Region USD Million (2018-2023)
  • Table 4. Hospital Acquired Pneumonia Swab , by Region USD Million (2018-2023)
  • Table 5. Hospital Acquired Pneumonia Moisturizer , by Region USD Million (2018-2023)
  • Table 6. Hospital Acquired Pneumonia Mouth Wash , by Region USD Million (2018-2023)
  • Table 7. Hospital Acquired Pneumonia Suction Tools , by Region USD Million (2018-2023)
  • Table 8. Hospital Acquired Pneumonia: by End-user(USD Million)
  • Table 9. Hospital Acquired Pneumonia Hospitals , by Region USD Million (2018-2023)
  • Table 10. Hospital Acquired Pneumonia Rehabilitation Centers , by Region USD Million (2018-2023)
  • Table 11. Hospital Acquired Pneumonia Home Care Settings , by Region USD Million (2018-2023)
  • Table 12. Hospital Acquired Pneumonia: by Drug Class(USD Million)
  • Table 13. Hospital Acquired Pneumonia Antibacterial drug , by Region USD Million (2018-2023)
  • Table 14. Hospital Acquired Pneumonia Antiviral drugs , by Region USD Million (2018-2023)
  • Table 15. Hospital Acquired Pneumonia Others , by Region USD Million (2018-2023)
  • Table 16. South America Hospital Acquired Pneumonia, by Country USD Million (2018-2023)
  • Table 17. South America Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 18. South America Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 19. South America Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 20. Brazil Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 21. Brazil Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 22. Brazil Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 23. Argentina Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 24. Argentina Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 25. Argentina Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 26. Rest of South America Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 27. Rest of South America Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 28. Rest of South America Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 29. Asia Pacific Hospital Acquired Pneumonia, by Country USD Million (2018-2023)
  • Table 30. Asia Pacific Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 31. Asia Pacific Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 32. Asia Pacific Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 33. China Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 34. China Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 35. China Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 36. Japan Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 37. Japan Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 38. Japan Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 39. India Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 40. India Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 41. India Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 42. South Korea Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 43. South Korea Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 44. South Korea Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 45. Taiwan Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 46. Taiwan Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 47. Taiwan Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 48. Australia Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 49. Australia Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 50. Australia Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 54. Europe Hospital Acquired Pneumonia, by Country USD Million (2018-2023)
  • Table 55. Europe Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 56. Europe Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 57. Europe Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 58. Germany Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 59. Germany Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 60. Germany Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 61. France Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 62. France Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 63. France Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 64. Italy Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 65. Italy Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 66. Italy Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 67. United Kingdom Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 68. United Kingdom Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 69. United Kingdom Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 70. Netherlands Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 71. Netherlands Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 72. Netherlands Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 73. Rest of Europe Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 74. Rest of Europe Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 75. Rest of Europe Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 76. MEA Hospital Acquired Pneumonia, by Country USD Million (2018-2023)
  • Table 77. MEA Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 78. MEA Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 79. MEA Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 80. Middle East Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 81. Middle East Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 82. Middle East Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 83. Africa Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 84. Africa Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 85. Africa Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 86. North America Hospital Acquired Pneumonia, by Country USD Million (2018-2023)
  • Table 87. North America Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 88. North America Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 89. North America Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 90. United States Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 91. United States Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 92. United States Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 93. Canada Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 94. Canada Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 95. Canada Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 96. Mexico Hospital Acquired Pneumonia, by Type USD Million (2018-2023)
  • Table 97. Mexico Hospital Acquired Pneumonia, by End-user USD Million (2018-2023)
  • Table 98. Mexico Hospital Acquired Pneumonia, by Drug Class USD Million (2018-2023)
  • Table 99. Hospital Acquired Pneumonia Sales: by Type(M Tons)
  • Table 100. Hospital Acquired Pneumonia Sales Oral Care Kit , by Region M Tons (2018-2023)
  • Table 101. Hospital Acquired Pneumonia Sales Toothbrush , by Region M Tons (2018-2023)
  • Table 102. Hospital Acquired Pneumonia Sales Swab , by Region M Tons (2018-2023)
  • Table 103. Hospital Acquired Pneumonia Sales Moisturizer , by Region M Tons (2018-2023)
  • Table 104. Hospital Acquired Pneumonia Sales Mouth Wash , by Region M Tons (2018-2023)
  • Table 105. Hospital Acquired Pneumonia Sales Suction Tools , by Region M Tons (2018-2023)
  • Table 106. Hospital Acquired Pneumonia Sales: by End-user(M Tons)
  • Table 107. Hospital Acquired Pneumonia Sales Hospitals , by Region M Tons (2018-2023)
  • Table 108. Hospital Acquired Pneumonia Sales Rehabilitation Centers , by Region M Tons (2018-2023)
  • Table 109. Hospital Acquired Pneumonia Sales Home Care Settings , by Region M Tons (2018-2023)
  • Table 110. Hospital Acquired Pneumonia Sales: by Drug Class(M Tons)
  • Table 111. Hospital Acquired Pneumonia Sales Antibacterial drug , by Region M Tons (2018-2023)
  • Table 112. Hospital Acquired Pneumonia Sales Antiviral drugs , by Region M Tons (2018-2023)
  • Table 113. Hospital Acquired Pneumonia Sales Others , by Region M Tons (2018-2023)
  • Table 114. South America Hospital Acquired Pneumonia Sales, by Country M Tons (2018-2023)
  • Table 115. South America Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 116. South America Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 117. South America Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 118. Brazil Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 119. Brazil Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 120. Brazil Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 121. Argentina Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 122. Argentina Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 123. Argentina Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 124. Rest of South America Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 125. Rest of South America Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 126. Rest of South America Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 127. Asia Pacific Hospital Acquired Pneumonia Sales, by Country M Tons (2018-2023)
  • Table 128. Asia Pacific Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 129. Asia Pacific Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 130. Asia Pacific Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 131. China Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 132. China Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 133. China Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 134. Japan Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 135. Japan Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 136. Japan Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 137. India Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 138. India Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 139. India Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 140. South Korea Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 141. South Korea Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 142. South Korea Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 143. Taiwan Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 144. Taiwan Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 145. Taiwan Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 146. Australia Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 147. Australia Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 148. Australia Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 149. Rest of Asia-Pacific Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 150. Rest of Asia-Pacific Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 151. Rest of Asia-Pacific Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 152. Europe Hospital Acquired Pneumonia Sales, by Country M Tons (2018-2023)
  • Table 153. Europe Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 154. Europe Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 155. Europe Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 156. Germany Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 157. Germany Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 158. Germany Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 159. France Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 160. France Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 161. France Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 162. Italy Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 163. Italy Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 164. Italy Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 165. United Kingdom Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 166. United Kingdom Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 167. United Kingdom Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 168. Netherlands Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 169. Netherlands Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 170. Netherlands Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 171. Rest of Europe Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 172. Rest of Europe Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 173. Rest of Europe Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 174. MEA Hospital Acquired Pneumonia Sales, by Country M Tons (2018-2023)
  • Table 175. MEA Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 176. MEA Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 177. MEA Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 178. Middle East Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 179. Middle East Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 180. Middle East Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 181. Africa Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 182. Africa Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 183. Africa Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 184. North America Hospital Acquired Pneumonia Sales, by Country M Tons (2018-2023)
  • Table 185. North America Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 186. North America Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 187. North America Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 188. United States Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 189. United States Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 190. United States Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 191. Canada Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 192. Canada Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 193. Canada Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 194. Mexico Hospital Acquired Pneumonia Sales, by Type M Tons (2018-2023)
  • Table 195. Mexico Hospital Acquired Pneumonia Sales, by End-user M Tons (2018-2023)
  • Table 196. Mexico Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2018-2023)
  • Table 197. Hospital Acquired Pneumonia: by Type(USD/Units)
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Hospital Acquired Pneumonia: by Type(USD Million)
  • Table 209. Hospital Acquired Pneumonia Oral Care Kit , by Region USD Million (2025-2030)
  • Table 210. Hospital Acquired Pneumonia Toothbrush , by Region USD Million (2025-2030)
  • Table 211. Hospital Acquired Pneumonia Swab , by Region USD Million (2025-2030)
  • Table 212. Hospital Acquired Pneumonia Moisturizer , by Region USD Million (2025-2030)
  • Table 213. Hospital Acquired Pneumonia Mouth Wash , by Region USD Million (2025-2030)
  • Table 214. Hospital Acquired Pneumonia Suction Tools , by Region USD Million (2025-2030)
  • Table 215. Hospital Acquired Pneumonia: by End-user(USD Million)
  • Table 216. Hospital Acquired Pneumonia Hospitals , by Region USD Million (2025-2030)
  • Table 217. Hospital Acquired Pneumonia Rehabilitation Centers , by Region USD Million (2025-2030)
  • Table 218. Hospital Acquired Pneumonia Home Care Settings , by Region USD Million (2025-2030)
  • Table 219. Hospital Acquired Pneumonia: by Drug Class(USD Million)
  • Table 220. Hospital Acquired Pneumonia Antibacterial drug , by Region USD Million (2025-2030)
  • Table 221. Hospital Acquired Pneumonia Antiviral drugs , by Region USD Million (2025-2030)
  • Table 222. Hospital Acquired Pneumonia Others , by Region USD Million (2025-2030)
  • Table 223. South America Hospital Acquired Pneumonia, by Country USD Million (2025-2030)
  • Table 224. South America Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 225. South America Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 226. South America Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 227. Brazil Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 228. Brazil Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 229. Brazil Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 230. Argentina Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 231. Argentina Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 232. Argentina Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 233. Rest of South America Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 234. Rest of South America Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 235. Rest of South America Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 236. Asia Pacific Hospital Acquired Pneumonia, by Country USD Million (2025-2030)
  • Table 237. Asia Pacific Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 238. Asia Pacific Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 239. Asia Pacific Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 240. China Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 241. China Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 242. China Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 243. Japan Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 244. Japan Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 245. Japan Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 246. India Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 247. India Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 248. India Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 249. South Korea Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 250. South Korea Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 251. South Korea Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 252. Taiwan Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 253. Taiwan Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 254. Taiwan Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 255. Australia Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 256. Australia Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 257. Australia Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 258. Rest of Asia-Pacific Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 259. Rest of Asia-Pacific Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 260. Rest of Asia-Pacific Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 261. Europe Hospital Acquired Pneumonia, by Country USD Million (2025-2030)
  • Table 262. Europe Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 263. Europe Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 264. Europe Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 265. Germany Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 266. Germany Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 267. Germany Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 268. France Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 269. France Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 270. France Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 271. Italy Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 272. Italy Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 273. Italy Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 274. United Kingdom Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 275. United Kingdom Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 276. United Kingdom Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 277. Netherlands Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 278. Netherlands Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 279. Netherlands Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 280. Rest of Europe Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 281. Rest of Europe Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 282. Rest of Europe Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 283. MEA Hospital Acquired Pneumonia, by Country USD Million (2025-2030)
  • Table 284. MEA Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 285. MEA Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 286. MEA Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 287. Middle East Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 288. Middle East Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 289. Middle East Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 290. Africa Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 291. Africa Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 292. Africa Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 293. North America Hospital Acquired Pneumonia, by Country USD Million (2025-2030)
  • Table 294. North America Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 295. North America Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 296. North America Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 297. United States Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 298. United States Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 299. United States Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 300. Canada Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 301. Canada Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 302. Canada Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 303. Mexico Hospital Acquired Pneumonia, by Type USD Million (2025-2030)
  • Table 304. Mexico Hospital Acquired Pneumonia, by End-user USD Million (2025-2030)
  • Table 305. Mexico Hospital Acquired Pneumonia, by Drug Class USD Million (2025-2030)
  • Table 306. Hospital Acquired Pneumonia Sales: by Type(M Tons)
  • Table 307. Hospital Acquired Pneumonia Sales Oral Care Kit , by Region M Tons (2025-2030)
  • Table 308. Hospital Acquired Pneumonia Sales Toothbrush , by Region M Tons (2025-2030)
  • Table 309. Hospital Acquired Pneumonia Sales Swab , by Region M Tons (2025-2030)
  • Table 310. Hospital Acquired Pneumonia Sales Moisturizer , by Region M Tons (2025-2030)
  • Table 311. Hospital Acquired Pneumonia Sales Mouth Wash , by Region M Tons (2025-2030)
  • Table 312. Hospital Acquired Pneumonia Sales Suction Tools , by Region M Tons (2025-2030)
  • Table 313. Hospital Acquired Pneumonia Sales: by End-user(M Tons)
  • Table 314. Hospital Acquired Pneumonia Sales Hospitals , by Region M Tons (2025-2030)
  • Table 315. Hospital Acquired Pneumonia Sales Rehabilitation Centers , by Region M Tons (2025-2030)
  • Table 316. Hospital Acquired Pneumonia Sales Home Care Settings , by Region M Tons (2025-2030)
  • Table 317. Hospital Acquired Pneumonia Sales: by Drug Class(M Tons)
  • Table 318. Hospital Acquired Pneumonia Sales Antibacterial drug , by Region M Tons (2025-2030)
  • Table 319. Hospital Acquired Pneumonia Sales Antiviral drugs , by Region M Tons (2025-2030)
  • Table 320. Hospital Acquired Pneumonia Sales Others , by Region M Tons (2025-2030)
  • Table 321. South America Hospital Acquired Pneumonia Sales, by Country M Tons (2025-2030)
  • Table 322. South America Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 323. South America Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 324. South America Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 325. Brazil Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 326. Brazil Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 327. Brazil Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 328. Argentina Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 329. Argentina Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 330. Argentina Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 331. Rest of South America Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 332. Rest of South America Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 333. Rest of South America Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 334. Asia Pacific Hospital Acquired Pneumonia Sales, by Country M Tons (2025-2030)
  • Table 335. Asia Pacific Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 336. Asia Pacific Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 337. Asia Pacific Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 338. China Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 339. China Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 340. China Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 341. Japan Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 342. Japan Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 343. Japan Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 344. India Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 345. India Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 346. India Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 347. South Korea Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 348. South Korea Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 349. South Korea Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 350. Taiwan Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 351. Taiwan Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 352. Taiwan Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 353. Australia Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 354. Australia Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 355. Australia Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 356. Rest of Asia-Pacific Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 357. Rest of Asia-Pacific Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 358. Rest of Asia-Pacific Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 359. Europe Hospital Acquired Pneumonia Sales, by Country M Tons (2025-2030)
  • Table 360. Europe Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 361. Europe Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 362. Europe Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 363. Germany Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 364. Germany Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 365. Germany Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 366. France Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 367. France Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 368. France Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 369. Italy Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 370. Italy Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 371. Italy Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 372. United Kingdom Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 373. United Kingdom Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 374. United Kingdom Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 375. Netherlands Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 376. Netherlands Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 377. Netherlands Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 378. Rest of Europe Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 379. Rest of Europe Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 380. Rest of Europe Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 381. MEA Hospital Acquired Pneumonia Sales, by Country M Tons (2025-2030)
  • Table 382. MEA Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 383. MEA Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 384. MEA Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 385. Middle East Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 386. Middle East Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 387. Middle East Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 388. Africa Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 389. Africa Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 390. Africa Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 391. North America Hospital Acquired Pneumonia Sales, by Country M Tons (2025-2030)
  • Table 392. North America Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 393. North America Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 394. North America Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 395. United States Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 396. United States Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 397. United States Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 398. Canada Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 399. Canada Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 400. Canada Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 401. Mexico Hospital Acquired Pneumonia Sales, by Type M Tons (2025-2030)
  • Table 402. Mexico Hospital Acquired Pneumonia Sales, by End-user M Tons (2025-2030)
  • Table 403. Mexico Hospital Acquired Pneumonia Sales, by Drug Class M Tons (2025-2030)
  • Table 404. Hospital Acquired Pneumonia: by Type(USD/Units)
  • Table 405. Research Programs/Design for This Report
  • Table 406. Key Data Information from Secondary Sources
  • Table 407. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hospital Acquired Pneumonia: by Type USD Million (2018-2023)
  • Figure 5. Global Hospital Acquired Pneumonia: by End-user USD Million (2018-2023)
  • Figure 6. Global Hospital Acquired Pneumonia: by Drug Class USD Million (2018-2023)
  • Figure 7. South America Hospital Acquired Pneumonia Share (%), by Country
  • Figure 8. Asia Pacific Hospital Acquired Pneumonia Share (%), by Country
  • Figure 9. Europe Hospital Acquired Pneumonia Share (%), by Country
  • Figure 10. MEA Hospital Acquired Pneumonia Share (%), by Country
  • Figure 11. North America Hospital Acquired Pneumonia Share (%), by Country
  • Figure 12. Global Hospital Acquired Pneumonia: by Type M Tons (2018-2023)
  • Figure 13. Global Hospital Acquired Pneumonia: by End-user M Tons (2018-2023)
  • Figure 14. Global Hospital Acquired Pneumonia: by Drug Class M Tons (2018-2023)
  • Figure 15. South America Hospital Acquired Pneumonia Share (%), by Country
  • Figure 16. Asia Pacific Hospital Acquired Pneumonia Share (%), by Country
  • Figure 17. Europe Hospital Acquired Pneumonia Share (%), by Country
  • Figure 18. MEA Hospital Acquired Pneumonia Share (%), by Country
  • Figure 19. North America Hospital Acquired Pneumonia Share (%), by Country
  • Figure 20. Global Hospital Acquired Pneumonia: by Type USD/Units (2018-2023)
  • Figure 21. Global Hospital Acquired Pneumonia share by Players 2023 (%)
  • Figure 22. Global Hospital Acquired Pneumonia share by Players (Top 3) 2023(%)
  • Figure 23. Global Hospital Acquired Pneumonia share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 27. Achaogen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Achaogen, Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Cubist Pharmaceutical (United States) Revenue, Net Income and Gross profit
  • Figure 30. Cubist Pharmaceutical (United States) Revenue: by Geography 2023
  • Figure 31. Aridis Pharmaceutical (United States) Revenue, Net Income and Gross profit
  • Figure 32. Aridis Pharmaceutical (United States) Revenue: by Geography 2023
  • Figure 33. Bayer Healthcare (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Bayer Healthcare (Germany) Revenue: by Geography 2023
  • Figure 35. AstraZeneca PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. AstraZeneca PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 37. Basilea Pharmaceutica Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 38. Basilea Pharmaceutica Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 39. Merck & Co., Inc., (United States) Revenue, Net Income and Gross profit
  • Figure 40. Merck & Co., Inc., (United States) Revenue: by Geography 2023
  • Figure 41. Meiji Seika Pharma Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 42. Meiji Seika Pharma Co., Ltd. (Japan) Revenue: by Geography 2023
  • Figure 43. Valneva SE. (France) Revenue, Net Income and Gross profit
  • Figure 44. Valneva SE. (France) Revenue: by Geography 2023
  • Figure 45. Global Hospital Acquired Pneumonia: by Type USD Million (2025-2030)
  • Figure 46. Global Hospital Acquired Pneumonia: by End-user USD Million (2025-2030)
  • Figure 47. Global Hospital Acquired Pneumonia: by Drug Class USD Million (2025-2030)
  • Figure 48. South America Hospital Acquired Pneumonia Share (%), by Country
  • Figure 49. Asia Pacific Hospital Acquired Pneumonia Share (%), by Country
  • Figure 50. Europe Hospital Acquired Pneumonia Share (%), by Country
  • Figure 51. MEA Hospital Acquired Pneumonia Share (%), by Country
  • Figure 52. North America Hospital Acquired Pneumonia Share (%), by Country
  • Figure 53. Global Hospital Acquired Pneumonia: by Type M Tons (2025-2030)
  • Figure 54. Global Hospital Acquired Pneumonia: by End-user M Tons (2025-2030)
  • Figure 55. Global Hospital Acquired Pneumonia: by Drug Class M Tons (2025-2030)
  • Figure 56. South America Hospital Acquired Pneumonia Share (%), by Country
  • Figure 57. Asia Pacific Hospital Acquired Pneumonia Share (%), by Country
  • Figure 58. Europe Hospital Acquired Pneumonia Share (%), by Country
  • Figure 59. MEA Hospital Acquired Pneumonia Share (%), by Country
  • Figure 60. North America Hospital Acquired Pneumonia Share (%), by Country
  • Figure 61. Global Hospital Acquired Pneumonia: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc (United Kingdom)
  • Achaogen, Inc. (United States)
  • Cubist Pharmaceutical (United States)
  • Aridis Pharmaceutical (United States)
  • Bayer Healthcare (Germany)
  • AstraZeneca PLC (United Kingdom)
  • Basilea Pharmaceutica Ltd. (Switzerland)
  • Merck & Co., Inc., (United States)
  • Meiji Seika Pharma Co., Ltd. (Japan)
  • Valneva SE. (France)
Select User Access Type

Key Highlights of Report


Mar 2024 235 Pages 88 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hospital Acquired Pneumonia Market Quantitative research analysis
Global Hospital Acquired Pneumonia Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline plc (United Kingdom), Achaogen, Inc. (United States), Cubist Pharmaceutical (United States), Aridis Pharmaceutical (United States), Bayer Healthcare (Germany), AstraZeneca PLC (United Kingdom), Basilea Pharmaceutica Ltd. (Switzerland), Merck & Co., Inc., (United States), Meiji Seika Pharma Co., Ltd. (Japan) and Valneva SE. (France) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising Demand in Combination Therapy for the Treatment of HAP" is seen as one of major influencing trends for Hospital Acquired Pneumonia Market during projected period 2023-2030.
The Hospital Acquired Pneumonia market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Hospital Acquired Pneumonia Market Report?

Have a Query? Click Here

Other Related Reports

Opioid Tolerance Treatment Comprehensive Study by Opioid Tolerance (Innate Tolerance, Acquired Tolerance), Route of Administration (Enteral, Parenteral, Others), Drug Analysis (NMDA Antagonists, Alph...
$ 3450
Glial Cell Line Derived Neurotrophic Factor Comprehensive Study by Type (GSK-812, LAUR-301, TW-002, AMT-090, Other), Application (Amyotrophic Lateral Sclerosis, Brain Ischemia, Parkinson’s Disease, R...
$ 3350
Expressed Competent Cells Comprehensive Study by Type (Chemically Competent Cells, Electro-Competent Cells), Application (Plasmid DNA, Bacterial Transformation, Cloning), Method (Natural Competence, ...
$ 3800
Plate Spreader Comprehensive Study by Type (Biochemical analysis, Biology lab equipment, Blood analysis system, Others), Application (Hospitals, Clinics, Laboratories), Usage Form (Cell holder, Bacte...
$ 3650
Partial Knee Replacement (PKR) Comprehensive Study by Application (Hospitals, Ambulatory Surgical Centers, Orthopedic Clinics, Others), Implant (Fixed-Bearing Implants, Mobile-Bearing Implants, Media...
$ 3800
Biosimilars Treatment Comprehensive Study by Type (Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone (RHGH), Granulocyte Colony-Stimulating Factor (Filgrastim), Insulin, Interfe...
$ 3750